ES2818902T3 - Novedosa forma cristalina de la sal 1-(5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4-metoxi-1H-pirrol-3-il)-N-metilmetanamina - Google Patents

Novedosa forma cristalina de la sal 1-(5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4-metoxi-1H-pirrol-3-il)-N-metilmetanamina Download PDF

Info

Publication number
ES2818902T3
ES2818902T3 ES17770546T ES17770546T ES2818902T3 ES 2818902 T3 ES2818902 T3 ES 2818902T3 ES 17770546 T ES17770546 T ES 17770546T ES 17770546 T ES17770546 T ES 17770546T ES 2818902 T3 ES2818902 T3 ES 2818902T3
Authority
ES
Spain
Prior art keywords
crystalline form
difluorophenyl
methoxy
fluorophenyl
sulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17770546T
Other languages
English (en)
Spanish (es)
Inventor
Aeri Kim
Kwan Hyung Cho
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daewoong Pharmaceutical Co Ltd
Original Assignee
Daewoong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Pharmaceutical Co Ltd filed Critical Daewoong Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2818902T3 publication Critical patent/ES2818902T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48Sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
ES17770546T 2016-03-25 2017-03-17 Novedosa forma cristalina de la sal 1-(5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4-metoxi-1H-pirrol-3-il)-N-metilmetanamina Active ES2818902T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020160036080A KR102081920B1 (ko) 2016-03-25 2016-03-25 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민 염의 신규한 결정형
PCT/KR2017/002914 WO2017164576A1 (fr) 2016-03-25 2017-03-17 Nouvelle forme cristalline de sel de 1-(5-(2,4-difluorophényl)-l-((3-fluorophényl)sulfonyl)-4-méthoxy-1h-pyrrol-3-yl)-n-méthylméthanamine

Publications (1)

Publication Number Publication Date
ES2818902T3 true ES2818902T3 (es) 2021-04-14

Family

ID=59900401

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17770546T Active ES2818902T3 (es) 2016-03-25 2017-03-17 Novedosa forma cristalina de la sal 1-(5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4-metoxi-1H-pirrol-3-il)-N-metilmetanamina

Country Status (32)

Country Link
US (6) US10336695B2 (fr)
EP (1) EP3433233B1 (fr)
JP (1) JP6554617B2 (fr)
KR (1) KR102081920B1 (fr)
CN (1) CN108602772B (fr)
AR (1) AR107963A1 (fr)
AU (1) AU2017238918B2 (fr)
BR (1) BR112018069461A2 (fr)
CA (1) CA3014745C (fr)
CL (3) CL2018002416A1 (fr)
CO (1) CO2018008833A2 (fr)
DO (1) DOP2018000190A (fr)
EA (1) EA029995B1 (fr)
ES (1) ES2818902T3 (fr)
HK (1) HK1254393A1 (fr)
HR (1) HRP20201594T1 (fr)
HU (1) HUE053502T2 (fr)
JO (1) JOP20170070B1 (fr)
MA (1) MA43833B1 (fr)
MX (1) MX2018009219A (fr)
MY (1) MY196299A (fr)
NZ (1) NZ745266A (fr)
PE (1) PE20190170A1 (fr)
PH (1) PH12018501846B1 (fr)
PL (1) PL3433233T3 (fr)
PT (1) PT3433233T (fr)
RS (1) RS60884B1 (fr)
SG (1) SG11201806966SA (fr)
SI (1) SI3433233T1 (fr)
TN (1) TN2018000288A1 (fr)
TW (1) TWI626234B (fr)
WO (1) WO2017164576A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102081920B1 (ko) 2016-03-25 2020-02-26 주식회사 대웅제약 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민 염의 신규한 결정형
KR102233456B1 (ko) 2017-05-31 2021-03-29 주식회사 대웅제약 4-메톡시피롤 유도체의 중간체 제조 방법
KR102233455B1 (ko) * 2017-06-21 2021-03-29 주식회사 대웅제약 4-메톡시피롤 유도체의 중간체 제조 방법
KR102126576B1 (ko) * 2018-09-19 2020-06-24 주식회사 대웅제약 4-메톡시 피롤 유도체의 제조 방법
EP4079293A4 (fr) * 2019-12-18 2024-01-03 Daewoong Pharmaceutical Co., Ltd. Composition pharmaceutique liquide de 1-(5-(2,4-difluorophényl)-1-((3-fluorophényl)sulfonyl)-4-méthoxy-1h-pyrrol-3-yl)-n-méthylméthaneamine
CN117820193A (zh) * 2022-09-29 2024-04-05 安徽皓元药业有限公司 一种非苏拉赞盐酸盐晶型a及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2582777A1 (fr) * 2004-09-30 2006-04-06 Takeda Pharmaceutical Company Limited Inhibiteurs de pompe a protons
ME00610B (fr) 2005-08-30 2011-12-20 Takeda Pharmaceuticals Co Dérivés de 1-h-pyrrole substitués par un groupe 1-hétérocyclylsulfonyle, 2-aminométhyle, 5-(hétéro)aryle en tant qu'inhibiteurs des sécrétions acides
JP5207964B2 (ja) * 2006-03-31 2013-06-12 武田薬品工業株式会社 酸分泌抑制薬
US20100113524A1 (en) * 2006-09-19 2010-05-06 Garst Michael E Prodrugs of proton pump inhibitors including the (1h-pyrrol-1-yl)-1h-benzimidazole moiety
US8933105B2 (en) * 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
KR20150084974A (ko) 2012-11-19 2015-07-22 장쑤 한서 파마슈티칼 캄파니 리미티드 피롤 설폰아미드 유도체, 이의 제조 방법, 및 이의 의학적 적용
KR102084185B1 (ko) 2013-08-29 2020-03-04 주식회사 대웅제약 테트라히드로사이클로펜타피롤 유도체 및 이의 제조방법
CN104447491B (zh) * 2014-11-19 2017-06-23 连云港恒运医药有限公司 含吡咯环质子泵抑制剂的半富马酸盐及其中间体和医药用途
CN104447490B (zh) * 2014-11-19 2017-06-06 连云港恒运医药有限公司 一种质子泵抑制剂的晶型、制备中间体及其合成方法和医药用途
KR101613245B1 (ko) * 2015-04-27 2016-04-18 주식회사 대웅제약 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
KR20170113040A (ko) * 2016-03-25 2017-10-12 주식회사 대웅제약 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민의 신규한 산부가염
KR102081920B1 (ko) 2016-03-25 2020-02-26 주식회사 대웅제약 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민 염의 신규한 결정형
KR102233456B1 (ko) 2017-05-31 2021-03-29 주식회사 대웅제약 4-메톡시피롤 유도체의 중간체 제조 방법
KR102233455B1 (ko) 2017-06-21 2021-03-29 주식회사 대웅제약 4-메톡시피롤 유도체의 중간체 제조 방법
KR102126576B1 (ko) 2018-09-19 2020-06-24 주식회사 대웅제약 4-메톡시 피롤 유도체의 제조 방법

Also Published As

Publication number Publication date
KR20170111170A (ko) 2017-10-12
HUE053502T2 (hu) 2021-07-28
US11858894B2 (en) 2024-01-02
US10683268B2 (en) 2020-06-16
EA201790454A3 (ru) 2017-11-30
TWI626234B (zh) 2018-06-11
PL3433233T3 (pl) 2020-12-14
US20200181082A1 (en) 2020-06-11
CA3014745C (fr) 2020-04-28
US10336695B2 (en) 2019-07-02
CA3014745A1 (fr) 2017-09-28
EA201790454A2 (ru) 2017-09-29
US20190322622A1 (en) 2019-10-24
JP2019509308A (ja) 2019-04-04
US20190047953A1 (en) 2019-02-14
AR107963A1 (es) 2018-07-04
MA43833B1 (fr) 2020-08-31
TN2018000288A1 (en) 2020-01-16
MX2018009219A (es) 2018-09-10
HRP20201594T1 (hr) 2020-12-11
PE20190170A1 (es) 2019-02-01
PT3433233T (pt) 2020-08-03
RS60884B1 (sr) 2020-11-30
PH12018501846A1 (en) 2019-05-15
JOP20170070B1 (ar) 2021-08-17
CL2020001826A1 (es) 2020-12-11
US11459297B2 (en) 2022-10-04
BR112018069461A2 (pt) 2019-02-12
NZ745266A (en) 2020-03-27
MY196299A (en) 2023-03-24
CN108602772A (zh) 2018-09-28
EP3433233B1 (fr) 2020-07-22
WO2017164576A1 (fr) 2017-09-28
EP3433233A4 (fr) 2019-08-14
TW201736343A (zh) 2017-10-16
US10889545B2 (en) 2021-01-12
SG11201806966SA (en) 2018-09-27
EP3433233A1 (fr) 2019-01-30
DOP2018000190A (es) 2018-09-30
SI3433233T1 (sl) 2020-10-30
JP6554617B2 (ja) 2019-07-31
AU2017238918A1 (en) 2018-08-16
CN108602772B (zh) 2021-06-04
AU2017238918B2 (en) 2019-05-09
PH12018501846B1 (en) 2019-05-15
US20200123106A1 (en) 2020-04-23
CL2020000186A1 (es) 2020-08-07
EA029995B1 (ru) 2018-06-29
US20210139424A1 (en) 2021-05-13
CL2018002416A1 (es) 2018-12-28
CO2018008833A2 (es) 2018-09-28
US20230159454A1 (en) 2023-05-25
HK1254393A1 (zh) 2019-07-19
AU2017238918A8 (en) 2018-08-30
WO2017164576A8 (fr) 2018-08-09
KR102081920B1 (ko) 2020-02-26
US10913715B2 (en) 2021-02-09

Similar Documents

Publication Publication Date Title
ES2811478T3 (es) Nueva sal de adición de ácido de 1-(5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4-metoxi-1H-pirrol-3-il)-N-metilmetanamina
ES2818902T3 (es) Novedosa forma cristalina de la sal 1-(5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4-metoxi-1H-pirrol-3-il)-N-metilmetanamina
ES2952770T3 (es) Formas de estado sólido de apalutamida
EP3218351B1 (fr) Procédé de préparation, d'isolation et de purification de formes pharmaceutiquement applicables de ahu-377
EP1919893A2 (fr) Formes polymorphes de mésylate d'imatinibe et procédés de préparation de nouvelles formes cristallines et amorphes et de forme
ES2879294T3 (es) Formas polimórficas de Belinostat y procesos para la preparación de las mismas
US8933114B2 (en) Polymorphic forms of asenapine maleate and processes for their preparation
WO2017164575A1 (fr) Nouveau sel d'addition d'acide de 1-(5-(2,4-difluorophényl)-1-((3-fluorophényl)sulfonyl)-4-méthoxy-1h-pyrrol-3-yl)-n-méthylméthanamine
US8598201B2 (en) Polymorphs of 6-(piperidin-4-yloxy)-2H-isoquinolin-1-one hydrochloride
EP4330255A1 (fr) Procédés de synthèse de valbénazine